Can Fite Biopharma

Can Fite Biopharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Can Fite Biopharma (CANF.TA) as of Oct 17, 2026 is -10.77 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -8.13 M USD — a change of 32.48% (lower).

EBITDA

-10.77 MUSD

YoY

32.48%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Can Fite Biopharma is 2025 -10.77 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Can Fite Biopharma was 2024 -8.13 M USD. It decreases by 32.48% lower compared to the previous year.

The Can Fite Biopharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-5.41 M USD
Jan 1, 2019
-12.01 M USD
Jan 1, 2020
-14.14 M USD
Jan 1, 2021
-12.84 M USD
Jan 1, 2022
-10.10 M USD
Jan 1, 2023
-8.20 M USD
Jan 1, 2024
-8.13 M USD
Jan 1, 2025
-10.77 M USD
The Can Fite Biopharma EBITDA history
YEAREBITDAYoY
-10.77 MUSD+32.48%
-8.13 MUSD-0.79%
-8.20 MUSD-18.83%
-10.10 MUSD-21.38%
-12.84 MUSD-9.17%
-14.14 MUSD+17.76%
-12.01 MUSD+121.78%
-5.41 MUSD-26.41%
-7.36 MUSD-14.61%
-8.62 MUSD+34.72%
-6.40 MUSD+175.08%
-2.32 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Can Fite Biopharma Stock analysis

What does Can Fite Biopharma do? Can-Fite Biopharma Ltd. is an Israeli company specializing in the development of drugs for inflammatory diseases and cancer. It was founded in 1994 by Prof. Pnina Fishman and is headquartered in Petach Tikva, Israel. The company initially focused on studying the function of adenosine receptors in central nervous system diseases, but later expanded to develop drugs for inflammatory diseases and cancer. Can-Fite went public in 2007 and has been able to finance its research projects through investors and partnerships. The company's business model revolves around developing an innovative portfolio of drugs for immune system disorders and cancer by targeting adenosine receptors. It aims to expand its drug pipeline to successfully treat a wide range of diseases. Can-Fite's drug pipeline is divided into different areas, including inflammatory diseases, cancer, and ophthalmology. The company has already brought several drugs to market or is in the clinical testing phase, including CF101 for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer, and Piclidenoson for autoimmune diseases. Overall, Can-Fite Biopharma Ltd. is a promising company focused on developing innovative drugs for inflammatory diseases and cancer. Can Fite Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Can Fite Biopharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Can Fite Biopharma is -10.77 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Can Fite Biopharma changed from -8.13 M USD to -10.77 M USD, representing a 32.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Can Fite Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Can Fite Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Can Fite Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Can Fite Biopharma